{
    "clinical_study": {
        "@rank": "134566", 
        "arm_group": [
            {
                "arm_group_label": "Experimental arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Nintedanib/vargatef"
            }, 
            {
                "arm_group_label": "Comparator arm", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Indication:\n\n      Treatment of subjects with advanced (FIGO stage IVB) or recurrent cervical cancer, prior\n      radiochemotherapy or neo-adjuvant chemotherapy is allowed.\n\n      Study design:\n\n      This is a phase II randomized, double blind and placebo controlled trial evaluating the\n      efficacy of Nintedanib/placebo in combination with the standard of 6 cycles 3 weekly\n      carboplatin and paclitaxel followed by Nintedanib/placebo maintenance in the treatment of\n      patients with advanced or recurrent cervical cancer.\n\n      A total of 120 patients will be randomized between the experimental and control arm in a 1:1\n      ratio. Randomization will be stratified for 1previous therapy (chemo-radiotherapy or\n      neoadjuvant chemotherapy: no, >6 months since last platin course) and 2disease status (Stage\n      IVB primary versus recurrent disease).\n\n      Experimental arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5 or 6) +\n      paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until\n      progression or for a total maximum duration of 120 weeks.\n\n      Control arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5 or 6) +\n      paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until\n      progression or for a total maximum duration of 120 weeks.\n\n      Subjects without evidence of disease progression after completion or discontinuation of the\n      study treatment will be followed until radiographic disease progression, withdrawal of\n      consent or death."
        }, 
        "brief_title": "ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer", 
        "completion_date": {
            "#text": "July 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Uterine Cervical Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Uterine Cervical Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female subjects more than 18 years of age\n\n          -  Histologically or cytologically confirmed advanced ([FIGO] stage IVB), or\n             recurrent/persistent squamous cell carcinoma, adenosquamous carcinoma, or\n             adenocarcinoma of the cervix will be eligible.\n\n          -  No prior chemotherapy for recurrent cervical cancer.\n\n               -  Prior concomitant cisplatinum chemotherapy during radiotherapy is allowed\n                  (except if recurrence is within 6 months after the end of the platinum\n                  containing chemotherapy).\n\n               -  Cases primarily treated with neoadjuvant chemotherapy before radical local\n                  surgery are eligible at the time of first recurrence. (except if recurrence is\n                  within 6 months after the end of the platinum containing chemotherapy).\n\n               -  Cases primarily treated with neoadjuvant chemotherapy before radical local\n                  surgery followed by adjuvant radiochemotherapy are eligible at the time of first\n                  recurrence (except if recurrence is within 6 months after the end of the\n                  platinum containing chemotherapy).\n\n               -  Cases primarily treated with neoadjuvant chemotherapy before radical local\n                  surgery followed by adjuvant radiotherapy are eligible at the time of first\n                  recurrence (except if recurrence is within 6 months after the end of the\n                  platinum containing chemotherapy).\n\n          -  Life expectancy at least  3 months.\n\n          -  ECOG Performance status score of 0 or 1\n\n          -  At least one measurable lesion according to RECIST 1.1 criteria\n\n          -  Signed and dated written informed consent prior to admission to the study in\n             accordance with ICH-GCP guidelines and to the local legislation\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy except platin-based concomitant chemotherapy during radiotherapy\n\n          -  - Prior  chemotherapy for advanced (FIGO stage IVB) or recurrent disease except as\n             mentioned in point 3.1.3.\n\n          -  Prior treatment with nintedanib or any other VEGFR inhibitor.\n\n          -  Known hypersensitivity to the trial drugs or to their excipients.\n\n          -  Brain or leptomeningeal metastases.\n\n          -  Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of\n             major blood vessels.\n\n          -  Tumor infiltrating the mucosa of the bowel or bladder, or known fistulas between the\n             tumor and the gastrointestinal or urinary tract.\n\n          -  Treatment with other investigational drugs or treatment in another clinical trial\n             within the past 4 weeks before start of therapy or concomitantly with the trial.\n\n          -  Therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed\n             for maintenance of an in-dwelling intravenous device) or anti-platelet therapy\n             (except for low-dose therapy with acetylsalicylic acid < 325mg per day.\n\n          -  Major injuries within the past 10 days prior to start of study treatment  with\n             incomplete wound healing and/or planned surgery during the on-treatment study period.\n\n          -  History of clinically significant haemorrhagic or thromboembolic event in the past 6\n             months.\n\n          -  Known inherited predisposition to bleeding or thrombosis.\n\n          -  Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina\n             within the past 6 months, history of infarction within the past 6 months prior to\n             start of study treatment, congestive heart failure > NYHA II, serious cardiac\n             arrhythmia, pericardial effusion).\n\n          -  History of a cerebral vascular accident, transient ischemic attack or subarachnoid\n             haemorrhage within the past 6 months.\n\n          -  Abnormal renal, liver or bone marrow function defined as:\n\n               -  Proteinuria CTCAE grade 2 or greater\n\n               -  Creatinin > 2 ULN or GFR < 30 ml/min\n\n               -  Hepatic function: total bilirubin outside of normal limits; ALT or AST > 1.5 ULN\n                  in pts without liver metastasis. For Pts with liver metastases: total bilirubin\n                  outside of normal limits, ALT or AST > 2.5 ULN\n\n               -  Coagulation parameters: International normalised ratio (INR) > 2, prothrombin\n                  time (PT) and partial thromboplastin time (PTT) > 50% of deviation  of\n                  institutional ULN\n\n               -  Absolute neutrophil count ( ANC) < 1500/\u00b5l, platelets < 100000/\u00b5l,  haemoglobin\n                   < 9.0 g/dl\n\n          -  Other malignancies within the past 3 years or other malignancy with recurrence in the\n             past 3 years or with high risk of recurrence in the first year. In exception to this\n             rule, the following malignancies may be included: non-melanomatous skin cancer (if\n             adequately treated) , any premalignant (e.g. in situ) carcinoma, or basocellular\n             carcinoma.\n\n          -  Active serious infections in particular if requiring systemic antibiotic or\n             antimicrobial therapy.\n\n          -  Active or chronic hepatitis C and/or B infection or known HIV infection.\n\n          -  Gastrointestinal disorders or abnormalities that would  interfere with absorption of\n             the study drug.\n\n          -  Serious illness or concomitant non-oncological disease such as neurologic,\n             psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or\n             laboratory abnormality that may increase the risk associated with study participation\n             or study drug administration and in the judgment of the investigator would make the\n             patient inappropriate for entry into the study.\n\n          -  Patients of child-bearing potential who are sexually active and unwilling to use a\n             medically acceptable method of contraception (e.g. such as implants, injectables,\n             combined oral contraceptives, some intrauterine devices or vasectomized partner or\n             sexual abstinence for participating females) during the trial and for at least three\n             months after end of active therapy.\n\n          -  Pregnancy or breast feeding, female patients must have a negative pregnancy test\n             (\u03b2-HCG test in urine or serum) prior to commencing study treatment, if applicable.\n\n          -  Psychological, familial, sociological or geographical factors potentially hampering\n             compliance with the study protocol and follow-up schedule.\n\n          -  Active alcohol or drug abuse."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009579", 
            "org_study_id": "BGOG-cx1/ENGOT-cx1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental arm", 
                "description": "Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5 or 6) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.", 
                "intervention_name": "Nintedanib", 
                "intervention_type": "Drug", 
                "other_name": "Vargatef"
            }, 
            {
                "arm_group_label": "Comparator arm", 
                "description": "Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5 or 6) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Uterine Cervical Cancer", 
            "Paclitaxel", 
            "Carboplatin", 
            "Nintedanib"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "link": [
            {
                "description": "BGOG website", 
                "url": "http://www.bgog.eu/"
            }, 
            {
                "description": "ENGOT website", 
                "url": "http://www.esgo.org/engot/Pages/AboutENGOT.aspx"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium"
                    }, 
                    "name": "Institut Jules Bordet"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium"
                    }, 
                    "name": "CHU Saint-Pierre"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleroi", 
                        "country": "Belgium"
                    }, 
                    "name": "Grand Hopital de Charleroi"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium"
                    }, 
                    "name": "UZ Antwerpen"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kortijk", 
                        "country": "Belgium"
                    }, 
                    "name": "AZ Groeninge"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "UZ Leuven"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium"
                    }, 
                    "name": "CHR Citadelle"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Namur", 
                        "country": "Belgium"
                    }, 
                    "name": "Clinique et maternite St. Elisabeth"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yvoir", 
                        "country": "Belgium"
                    }, 
                    "name": "Cliniques Universitaires mont godinne"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "BGOG-cx1/ENGOT-cx1: \"Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma.\"", 
        "overall_contact": {
            "email": "bgog@engot.eu", 
            "last_name": "Ignace Vergote, MD", 
            "phone": "+32(0)16 344207"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary objective:\nThe purpose of this trial is to determine if chemotherapy (carboplatin/paclitaxel) plus Nintedanib (BIBF 1120) can improve progression free survival compared to chemotherapy (carboplatin/paclitaxel) plus placebo in patients with advanced or recurrent cervical cancer.", 
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "1.5 years after LPI"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary objectives:\nTo evaluate the safety and toxicity reported for of the combination regimen", 
                "measure": "Safety and toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "5 years after LPI"
            }, 
            {
                "description": "To evaluate the response rate according to RECIST 1.1", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years after LPI"
            }, 
            {
                "description": "To explore the  effect of Nintedanib on patient reported health status as measured by EORTC-QOL-Cx 24 and EORTCQLQ-C30 questionnaires", 
                "measure": "Patient health status", 
                "safety_issue": "No", 
                "time_frame": "5 years after LPI"
            }, 
            {
                "description": "To evaluate the overall survival", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years after LPI"
            }
        ], 
        "source": "Belgian Gynaecological Oncology Group", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Ovario", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Mario Negri Gynecologic Oncology group", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Multicenter Italian Trials in Ovarian Cancer", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Institute of Cancer Research, United Kingdom", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Belgian Gynaecological Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}